当前位置: 首页 > 期刊 > 《中国性科学》 > 2015年第9期
编号:12731483
HPV DNA检测在宫颈病变病人分层管理中的应用(4)
http://www.100md.com 2015年9月1日 《中国性科学》 2015年第9期
     [8]Munoz N, et al.Against which human papillomavirus types shall we vaccinate and screen?the international perspective. Int J Cancer, 2004,111(2):278-285.

    [9]Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer, 2009, 4(8): 1629.

    [10]Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus(HPV) testing and HPV 16 or HPV 18 genotyping for cervical cancer screening of women aged 25 years and older:a subanalysis of the ATHENA study. Lancet Oncol, 2011(12):880-890.

    [11]Silvia de Sanjose, et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional wordwide study. The Lancet, 2010,11(11):1048-1056.

    [12]Ito T, Ishizuka T, Suzuki K, et al.Cervical cancer in young Japanese women. Arch Gynecol Obstet,2000, 264(2):68-70.

    [13]Frega A, Stentella P, De Ioris A, et al. Young women,cervical intraepithelial neoplasia and human papillomavirus: risk factors for persisitence andrecurrence. Cancer Letters, 2003,196(2):127-134.

    [14]Sellors JW, Mahony LB, Kaczorowski J, et al. Prevalence and predictors of humanpapillomavirus infection in women in Ontario, Canada. CMAJ, 2000(163) :503-508.(收稿日期:2014-12-02), http://www.100md.com(苏丽 刘海清 席丽军 任晶 冯丽艳 英丹)
上一页1 2 3 4